EUVIMEDEUVIMED entdecken
Crossref

Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection

Dana Kablawi, Alshaima Alhinai, Philip Wong, Marc Deschenes, Giada Sebastiani iD, Amine Benmassaoud

HIV Medicine · 2023-03 · 24 (3) · 366-371

DOI: 10.1111/hiv.13390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 30.08.2022. Verfasst von Dana Kablawi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: HIV Infections, Hypertension, Portal, Elasticity Imaging Techniques. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: FRQS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the clinical significance of splenomegaly as a marker of underlying liver disease in people with HIV (PWH).

Methods

We included consecutive PWH from a prospective cohort from 2010 to 2020 with available liver stiffness measurement (LSM) and liver imaging to define splenomegaly (> 13 cm) within 1 year. Cut‐offs of LSM > 10 kPa and > 21 kPa were used to identify advanced chronic liver disease (ACLD) and portal hypertension, respectively. Logistic regression multivariable analysis was employed to identify independent predictors of ACLD.

Results

In all, 331 PWH were included, 76% of them men, with a median (interquartile range) age of 51.3 (45–58) years, all receiving antiretroviral treatment, and 53% were HIV monoinfected. The PWH with splenomegaly exhibited a higher prevalence of ACLD compared with those with normal spleen size, as per LSM (26% vs. 9%; p = 0.009). Portal hypertension diagnosed by LSM was also more prevalent in PWH with splenomegaly than in those without (15% vs. 2%; p < 0.001). Independent predictors of ACLD were viral hepatitis coinfection [adjusted odds ratio (aOR) = 3.15, 95% confidence interval (CI): 1.65–6.0], lower platelets (aOR = 0.99, 95% CI: 0.99–0.99) and splenomegaly (aOR = 2.41, 95% CI: 1.17–4.99). In patients with available oesophagogastroduodenoscopy, splenomegaly was also associated with higher prevalence of oesophageal varices and other endoscopic findings of portal hypertension (38% vs. 17%; p = 0.027).

Conclusions

Splenomegaly identified on routine imaging may have utility as a marker of ACLD and portal hypertension, prompting further investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHypertension, PortalElasticity Imaging TechniquesMaleHumansMiddle AgedLiver CirrhosisSplenomegalyProspective StudiesLiver

Stichwörter der Autor:innen

HIVliver stiffness measurementserum fibrosis biomarkerstransient elastography

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Québec, Canada.
  • Division of Experimental Medicine, McGill University, Montreal, Québec, Canada.

ORCID-Profile: Giada Sebastiani

Förderung

  • FRQS

Zitieren

APA

Kablawi, D., Alhinai, A., Wong, P., Deschenes, M., Sebastiani, G., & Benmassaoud, A. (2023). Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection. HIV Medicine, 24(3), 366-371. https://doi.org/10.1111/hiv.13390

Vancouver

Kablawi D, Alhinai A, Wong P, Deschenes M, Sebastiani G, Benmassaoud A. Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection. HIV Medicine. 2023;24(3):366-371. doi:10.1111/hiv.13390

BibTeX
@article{Kablawi2023,
  author = {Kablawi, Dana and Alhinai, Alshaima and Wong, Philip and Deschenes, Marc and Sebastiani, Giada and Benmassaoud, Amine},
  title = {Splenomegaly is a marker of advanced chronic liver disease and portal hypertension in HIV infection},
  journal = {HIV Medicine},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {366--371},
  doi = {10.1111/hiv.13390}
}
Kostenlos starten →